Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 2 days ago

Decoy Therapeutics Inc.: CVI Investments, Inc. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

CVI Investments, Inc. filed an amended Schedule 13G with the SEC (accession 0001649553-26-000138) updating its beneficial ownership stake in Decoy Therapeutics Inc. The amendment modifies the investment firm's previously reported position in the biotech company, though the filing did not disclose a change in share count or percentage ownership. Schedule 13G filings are required of passive investors holding more than 5% of a company's voting securities, making the update a routine but closely watched signal of institutional positioning. Investors will watch for further 13G or 13D filings to gauge whether CVI's stake remains passive or shifts toward activism.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

CVI Investments, Inc., Decoy Therapeutics Inc.